Fig 1: Tumor genomic profiles.(A) CGH profiles of four cases representing a leiomyoma (LM), a STUMP and the two mutated uterine leiomyosarcomas (LMS). (B) CGH profiles of four representative cases without MED12 expression. Genomic alterations are presented and organized from chromosome 1 to 22 and X, Y on the X axis and log2 ratio values are reported on the Y axis. Significant gains or losses are indicated by red lines and red areas above or below each profile, respectively.
Fig 2: MED12 mutations on cDNA.Sequence chromatographs of MED12 mutations observed on cDNA showing that the mutated allele is predominantly expressed. Arrows indicate mutation sites.
Fig 3: MED12 genomic mutationsSequence chromatograms showing MED12 mutations observed on genomic DNA in the nine mutated uterine LM, STUMP and LMS (Sequence viewer: FinchTV, Geospiza). Arrows indicate mutation sites.
Fig 4: MED12 protein expression.(A) Positive MED12 nuclear labeling in mutated LM6. (B) Positive MED12 nuclear staining in wild-type STUMP8. (C) Wild-type STUMP4 with negative staining (D) Mutated LMS1 without MED12 labeling. Magnification: X40.
Fig 5: MED12 RNA expression.(A) Expression profiles of MED12 and ß2M (ß-2-microglobulin) obtained by RT-PCR in uterine smooth muscle tumors are presented. ß2M is used as RT-PCR control. (B) Expression profiles of MED12 and ß2M (ß-2-microglobulin) obtained by RT-PCR in LMS from limbs and internal trunk are presented. *: mutated tumors. L: molecular weight ladder. LM: leiomyoma, LMS: leiomyosarcoma, STUMP: Smooth muscle Tumor of Uncertain Malignant Potential.
Supplier Page from MilliporeSigma for Anti-MED12 antibody produced in rabbit